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Background: Ankle-Foot-Orthoses with a ventral shell, also known as Floor Reaction Orthoses (FROs), are often
used to reduce gait-related problems in children with spastic cerebral palsy (SCP), walking with excessive knee
flexion. However, current evidence for the effectiveness (e.g. in terms of walking energy cost) of FROs is both
limited and inconclusive. Much of this ambiguity may be due to a mismatch between the FRO ankle stiffness and
the patient’s gait deviations.
The primary aim of this study is to evaluate the effect of FROs optimised for ankle stiffness on the walking energy
cost in children with SCP, compared to walking with shoes alone. In addition, effects on various secondary
outcome measures will be evaluated in order to identify possible working mechanisms and potential predictors of
FRO treatment success.
Method/Design: A pre-post experimental study design will include 32 children with SCP, walking with excessive
knee flexion in midstance, recruited from our university hospital and affiliated rehabilitation centres. All participants
will receive a newly designed FRO, allowing ankle stiffness to be varied into three configurations by means of a
hinge. Gait biomechanics will be assessed for each FRO configuration. The FRO that results in the greatest
reduction in knee flexion during the single stance phase will be selected as the subject’s optimal FRO.
Subsequently, the effects of wearing this optimal FRO will be evaluated after 12–20 weeks. The primary study
parameter will be walking energy cost, with the most important secondary outcomes being intensity of
participation, daily activity, walking speed and gait biomechanics.
Discussion: The AFO-CP trial will be the first experimental study to evaluate the effect of individually optimised
FROs on mobility and participation. The evaluation will include outcome measures at all levels of the International
Classification of Functioning, Disability and Health, providing a unique set of data with which to assess relationships
between outcome measures. This will give insights into working mechanisms of FROs and will help to identify
predictors of treatment success, both of which will contribute to improving FRO treatment in SCP in term.
Trial registration: This study is registered in the Dutch Trial Register as NTR3418.
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With an incidence of 2–3 per 1000 living births, Cerebral
Palsy (CP) is the most frequent cause of motor disorders
in childhood in Western countries [1]. Spastic motor dis-
orders are most common in children with CP, with symp-
toms of spasticity, muscle weakness and decreased
selective motor control [2], often causing limitations in
mobility [3], which may lead to a restricted participation
in everyday life [4].
Although more than half of all children with bilateral
spastic CP (SCP) walk independently with or without an
assistive device [5], most experience mobility-related
problems, such as reduced gait speed and/or an
increased walking energy cost [6-12]. These problems
are often caused by gait deviations [13-16], which can be
corrected by prescribing ankle-foot orthoses (AFOs). An
AFO imposes a mechanical constraint on the ankle, ei-
ther to compensate for loss of function [17-19] or to
counteract an excess of function [20,21]. An AFO there-
fore acts by applying control to the ankle and foot and,
dependent on its design, it can indirectly stabilise the
knee and hip joints [22]. As such, AFOs aim to improve,
i.e. normalise joint kinetics, joint kinematics and spatio-
temporal parameters [17,23-26]. Improvements in joint
kinetics and kinematics have been shown to be closely
coupled to an improved walking energy cost, which leads
to benefits in walking ability; an effect also noted in the
context of orthotic interventions [23,25-27]. This applies
especially to children who walk with excessive knee
flexion in midstance, since this walking pattern is par-
ticularly energy consuming [9,10] and these children are
liable to show deterioration in walking ability in (pre-)
puberty [28,29].
A variety of AFO types are available, depending on the
specific gait deviations of the child. For children who
walk with excessive knee flexion, orthoses with a ventral
shell, also known as Floor Reaction Orthoses (FROs), are
commonly prescribed [20]. Although FROs are widely
used in SCP, evidence supporting their effectiveness is so
far lacking. The decision-making process leading to FRO
prescription is still based on expert opinion and experi-
ence (i.e. a trial-and-error approach), resulting in differ-
ences in treatment paradigms with respect to both the
indication and the mechanical construction of FROs
[30,31]. This is reflected in current literature, as studies
have shown that wearing an FRO can be effective in de-
creasing walking energy cost, but may also have no effect
[32] or even be adverse in some children in terms of
walking energy cost or gait speed [26,32].
This variation in FRO effectiveness might be partly
explained by the match of the mechanical properties of
the orthosis to a patient’s specific gait deviations. Re-
search in adults with neurological disorders has shown
that walking energy cost with a typical spring-like AFOcould be optimised by choosing the correct AFO ankle
stiffness [33], suggesting that there may be an optimal
match between a patient’s characteristics and the mech-
anical properties of an AFO. A similar principal might
also apply to FROs.
A conventional FRO is a rigid type of AFO, and
includes a ventral shell and a rigid footplate. The bio-
mechanical mechanism of an FRO is to create a knee-
extensor moment during midstance and terminal stance,
by shifting of the ground reaction force forward [21]. Al-
though an FRO might be effective in this respect, ankle
push-off power is obstructed by an impeded plantar
flexion in terminal stance and preswing. To enhance
push-off power, a more spring-like FRO could poten-
tially be beneficial, since it could store energy at the be-
ginning of the stance phase that is released and returned
in preswing. Achieving a sufficiently high stiffness to
counteract knee flexion while including the potential
benefit of spring-like properties in terms of walking en-
ergy cost may result in an optimal FRO stiffness based
on the least compromise between these two goals.
Designing and evaluating the efficacy of such an opti-
mal FRO requires an evaluation of the effects of different
degrees of FRO ankle stiffness on various aspects of gait,
i.e. function, mobility and participation. This implies a
need for a set of outcome measures that covers all
domains of the International Classification of Function-
ing, Disability and Health (ICF) [34]. Evaluating the
effects of an intervention on more than one of the ICF
domains will provide insights into mutual relations,
thereby aiming to identify possible working mechanisms
[35], which will contribute to improved FRO treatment.
FRO treatment could be further improved by identify-
ing those children who could benefit from FROs [30].
Rogozinski et al. [21] explored clinical examination
parameters that might explain the efficacy of FROs in
CP children walking with excessive knee flexion. They
found a strong, negative correlation between knee and
hip flexion contractures and peak knee extension,
achieved during walking with an FRO. Other studies
have shown that child characteristics and environmental
factors predict the response to rehabilitation interven-
tions, such as Botulinum toxin A injections [36-38] and
surgery [39-41]. Specific patient characteristics might
also be relevant predictive factors for FRO efficacy.
In summary, evidence supporting the efficacy of FROs
in children with SCP walking with excessive knee flexion
remains inconclusive. Understanding of both the under-
lying working mechanisms and the factors predictive of
treatment success is still lacking. Therefore, this project
has two main goals:
1. To study the effect of an FRO optimised for ankle
stiffness on walking energy cost in children with SCP
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walking with shoes alone.
2. To identify the possible working mechanisms of an
FRO, and the predictors for success of FRO




A pre-post experimental study consisting of two repeated
measurements, i.e. at baseline, T0, walking with shoes only
(control), and at 12–20 weeks follow-up, T2Kopt, walking
with an optimised FRO (case) will be performed to evalu-
ate FRO efficacy in children with SCP (Figure 1). The
study protocol has been approved by the Medical Ethics
Committee of the VU University Medical Center in
Amsterdam.
Following completion of study enrolment, baseline mea-
surements (T0) will be performed barefoot, with shoes
only and with the subject’s current orthosis (if applicable).
Stiffness (K) of the new FRO will be varied into three con-
figurations: rigid, stiff, and flexible. A balanced block ran-
domisation will be applied for six possible sequences of
stiffness configurations, to ensure that the same number
of patients is allocated to each sequence. Every configur-
ation will be worn for an accommodation period of fourFigure 1 Schematic representation of the study design. Following base
interventional FRO. The stiffness of this FRO will be varied (rigid, stiff and fl
Accommodation time for each stiffness will last 4–8 weeks, after which effe
evaluations, an optimal FRO for the subject will be selected. Follow-up mea
FRO= Floor Reaction Orthosis; K=AFO stiffness; K1, K2, and K3 represent eithto eight weeks, after which FRO efficacy will be evaluated
(T1k1,T1K2 and T1K3). An analysis of the evaluation of all
FRO configurations will allow the selection of the stiffness
with the maximal benefit for a particular subject, referred
to as the subject’s optimal FRO (the selection procedure is
explained further below). Following this selection, the op-
timal FRO will be worn for twelve to twenty weeks, after
which the follow-up measurements (T2Kopt) will be taken.Participants
Inclusion and exclusion criteria
Our aim is to include 32 children with SCP (Gross
Motor Function Classification Score [42] (GMFCS)
levels I, II and III [provided that the child is able to per-
form a 3D-gait analysis without walking aids]) who are
candidates for a (new) FRO. Children will be recruited
from the outpatient clinic of the VU University Medical
Center, Amsterdam and affiliated rehabilitation centres.
Study information will be provided to potential partici-
pants in the form of a patient information letter and a
brochure. Patients and parents willing to participate will
be contacted by the primary investigator (YK), who will
verify inclusion and exclusion criteria (Table 1). When a
patient meets the inclusion criteria, oral and written
informed consent will be obtained from both parents,line measurements (T0), the subject’s will be prescribed an
exible) and the order of FRO stiffness will be block randomised.
cts will be evaluated (T1K1, T1K2, and T1K3). Following these
surements (T2Kopt) will be carried out at 12–20 weeks. B=Block;
er rigid, stiff or flexible stiffness configurations.




A gait pattern characterised by excessive knee flexion (jump gait, apparent equinus or crouch gait) [42];
GMFCS I, II, or III (provided that the patient is able to walk independently for at least 15 meters)
Exclusion criteria
Any orthopaedic surgery or other surgical interventions that might influence mobility in the past 6 months;
Botulinum toxin A injections in the past 3 months, Intrathecal Baclofen therapy in the past 6 months, or SDR in the past year;
Impairments that could contraindicate fitness testing;
Plantar flexion contractures or knee contractures >10° or hip endorotation > 20° in midstance;
Other medical conditions influencing mobility;
Severe behavioural problems;
GMFCS: Gross Motor Function Classification System [43]; SDR: Selective Dorsal Rhizotomy.
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ance with the declaration of Helsinki.
Sample size
The sample size will be based on a power analysis of the
expected changes (i.e. T0 versus T2) in the primary out-
come, walking energy cost [J-1⋅kg-1⋅m1]. According to lit-
erature, walking energy cost in children with CP may be
30-50% higher than in healthy children [10-12]. SCP
children with GMFCS levels I, II and III show a mean
net EC of 5.02 (±1.70) J-1⋅kg-1⋅m1 [26]. A reduction of
25% in this value (≈1.26 J-1⋅kg-1⋅m1) is considered to be
a clinically significant change [25,26]. Assuming a power
of 80% and a significance level of 0.05, detecting a clinic-
ally significant change will require a sample size of 29
children [44]. Allowing for a dropout of approximately
10%, a sample size of 32 will be sufficient.
Investigational AFO
Investigational FROs will be composed of prepreg car-
bon, manufactured using the Mälmo-technique (Otto
Bock HealthCare GmbH, Duderstadt, Germany). For fair
evaluation of efficacy, the investigational FRO will be
fabricated with a rigid footplate. To further ensure a fair
comparison, tuning of the FRO-footwear combination
following the Owen method will be carried out for each
configuration [45].
Investigational FROs will be fabricated with an
integrated Neuro SwingW system hinge (Fior & Gentz,
Lüneberg, Germany), which is available in different sizes.
The size of the hinge is dependent on the body weight
and length of the patient. For this study, it is expected
that only the 14mm and 16mm hinges will be used. The
hinge holds an anterior and posterior shaft, and comes
with a package of five springs, each with a different de-
gree of stiffness. Ankle stiffness can be adjusted withinthe same orthosis, using different spring forces towards
plantar and dorsal flexion. In this study, the hinge will
be prepared in three configurations: rigid, stiff and flex-
ible. The rigid configuration (i.e. ±4.3 Nm/deg) will en-
tirely prevent dorsal or plantar flexion. For the stiff and
flexible configurations, the spring force for dorsal flexion
will be varied using the strongest spring (i.e. ±1.2 Nm/deg
[14mm] and ±2.4 Nm/deg [16mm]) and the second stron-
gest spring (i.e. ±0.5 Nm/deg [14mm] and ±1.0 Nm/deg
[16mm]), respectively. The spring force towards plantar
flexion will be very compliant (i.e. ±0.01 Nm/deg [14mm]
and ±0.04 Nm/deg [16mm]) for both configurations.
Accommodation procedures
The accommodation period for all three FRO configura-
tions will include a gradual increase in the length of time
the FRO is worn each day, in order to minimise the risk
of adverse events. Patients will be contacted one week
after setting each new FRO configuration, to check for
adverse events such as pain, discomfort, or pressure
sores. If the patient has no complaints, the accommoda-
tion period will continue until the next visit (four to
eight weeks later). When adverse events are reported,
the investigator will identify the causes and make an ap-
propriate decision according to protocol. The accommo-
dation period will not start until all complaints are
resolved.
Optimal AFO selection procedure
Following a standard procedure, evaluation of FRO effi-
cacy of the three configurations (T1k1, T1K2 and T1K3)
will lead to selection of the subject’s optimal FRO con-
figuration (Figure 2). Since clinical assessment of FRO ef-
fectiveness in children walking with excessive knee flexion
is mainly based on knee kinematics in stance, the mini-
mum amount of knee flexion (i.e. peak knee extension) in
Figure 2 Flowchart of the optimal FRO stiffness selection procedure. After sorting the different stiffness configurations based on peak knee
extension angle in single support (KE-Kx), absolute differences in peak KE will be calculated. KE-K2 and/or KE-K3 will be excluded if this difference
is more than five degrees. Otherwise, the remaining configurations will be sorted by net non-dimensional walking energy cost (NNC-Kx) (this can
be either two or three remaining configurations). The stiffness that results in the lowest walking energy cost will be selected as the subject’s
optimal FRO. K1, K2 and K3 = rigid, stiff, or flexible FRO stiffness configurations; KOPT = subject’s optimal FRO stiffness; KE = knee extension angle;
KE-Kx = stiffness sorted by KE; NN_cost%SMC = net non-dimensional walking energy cost relative to speed matched controls; NNC-Kx = stiffness
sorted by NN_cost%SMC; SS = single support.
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parameter. The configuration that results in smallest peak
knee flexion will be selected as the subject’s optimal FRO.
Differences of less than 5º will be considered equal, since
this angle lies within the variability of 3D gait analysis
[46]. Should minimum knee flexion in single support be
unable to discriminate between the remaining configura-
tions, walking energy cost (expressed as net non-
dimensional energy cost relative to speed-matched control
cost (NN_EC%SMC) [47,48] will be decisive. In this situ-
ation, the FRO that results in the lowest NN_EC%SMC will
be selected as the subject’s optimal FRO.Outcome measures
Outcome measures for this study are categorised in ac-
cordance with the ICF [34] and cover the components
‘body functions and structures’ and ‘activities and partici-
pation’, as well as personal and environmental factors.
An overview of all outcome measures is presented in
Table 2.
Primary outcome
Our primary outcome measure is walking energy cost,
which will be measured during a 6-minute walking test
on an indoor oval track. Subjects will be asked to walk
at a self-preferred comfortable speed, during which oxy-
gen uptake and carbon dioxide production will be mea-
sured using the accurate and reliable Metamax 3B
portable gas analysis system (Cortex Biophysik, Leipzig,
Germany). Calculations will be based on measurements
during a steady state of walking, defined as a period of
at least one minute in which fluctuations in walkingspeed, oxygen uptake and carbon dioxide production
show the least change [48].
Mean steady-state breath-by-breath oxygen uptake
values and respiratory exchange ratios will be computed.
Using these values, gross and net energy consumption
will be calculated and normalised according to the net
non-dimensional (NN) scheme of Schwartz et al. [48].
The primary outcome measures will be expressed as net
energy cost and as NN energy cost as a percentage of
speed-matched controls (NN_EC%SMC). Furthermore,
non-dimensional walking speed (N_speed) (a secondary
outcome measure) will be calculated.
EC measurements in children with CP are sufficiently
sensitive, as shown by Brehm et al. [49]. The NN normal-
isation scheme of Schwartz et al. is suggested to be the
preferred method for reporting oxygen consumption data
for subjects who have not reached their full stature, since
it is largely independent of mass, height and age [48].
Secondary outcome
Secondary outcome measures include daily activity, gait
biomechanics, walking speed (N_speed) and diversity,
intensity and enjoyment of participation (assessed with the
Children’s Assessment of Participation and Enjoyment
[CAPE]). Two of these outcome measures (daily activity
and gait biomechanics) are further explained below.
Daily activity
Daily activity will be measured for one week with a Step-
Watch3™ Activity Monitor 3.0 (SAM) (Cyma Corporation
Seattle, WA, USA), which is an ankle worn accelerometer
that measures the average amount of steps per minute
over a broad spectrum of cadences. The SAM will be




Activities and participation ECWT x x x
Secondary study parameters
Body functions and structures 3D-gait analysis x x x
Activities and participation SAM*** x x x
CAPE*** x x
Effect modifiers









FMS x x x




FRO properties x x x
Motivation diary x x x
@ monitor x x
Satisfaction x x x
*T1k will be repeated for each FRO-configuration: rigid, stiff and flexible.
** The physical examination includes passive Range of Motion, selective motor
control and gross motor function tests.
***SAM and CAPE data will be assessed in the week prior to the ticked
measurement moment.
BSS=’Bronnen van Steun en Spanning’; CAPE=Children’s Assessment of
Participation and Enjoyment; ECWT=Energy Cost of Walking Test;
FAQ=Functional Assessment Questionnaire; FMS=Functional Mobility Scale;
FRO=Floor Reaction Orthosis; GAS=Goal Attainment Scaling; GMFCS=Gross
Motor Function Classification System; SAM=StepWatch3TM Activity Monitor.
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instructed not to remove the SAM at any time, except
when taking a bath or shower or when swimming. For ad-
equate interpretation of the data, subjects will be asked to
keep a diary of their activity program during each day of
the week.
Daily activity will be determined as 1) average total
steps per day, 2) percentage of time children were active,
3) percentage of time children were inactive, 4) ratio of
medium to low activity levels and 5) percentage of time
children show high activity levels. A calibrated SAM has
been shown to be an accurate tool for recording daily
steps in children with CP [50,51].
Gait biomechanics Joint kinematics will be assessed in
the laboratory, using a three-dimensional (3D) motion
analysis system (OptoTrak, Northern Digital, Waterloo,Canada), while the subject walks on a 10m walkway at a
self-preferred comfortable speed. Marker clusters will be
attached to the feet, shanks, thighs, pelvis and trunk. To
determine anatomical coordinate systems, anatomical
landmarks will be palpated according to Cappozzo et al.
[52]. Joint kinetics will be calculated by assessment of
the ground reaction force, using an integrated force plate
(AMTI OR6-5-1000, Watertown, MA, USA).
At baseline, all subjects will be measured walking bare
foot and with shoes only. An additional condition (old
FRO-footwear combination) will be included for chil-
dren who have (suitable) old orthoses. Follow-up record-
ings will be made while walking with the new FRO-
footwear combination. Six trials, with the subject step-
ping on the force plate, will be completed for each con-
dition (i.e. three trials for each leg). Data on joint
kinematics, and kinetics around the hip, knee and ankle
will be averaged. Spatio-temporal parameters, such as step
length [m], step width [m] and cadence [steps⋅min-1] will
also be calculated.
Effect modifiers
As potential effect modifiers, the following outcome
measures will be assessed: demographic variables,
disease characteristics, personal and family characteris-
tics, level of functional mobility and physical fitness
(explained below).
Physical fitness Physical fitness will be measured by
means of an aerobic and anaerobic exercise test on a bi-
cycle ergometer. The aerobic test will be performed
according to the protocol described by Balemans et al.
[53] and aerobic fitness will be defined as oxygen uptake
over the 30 seconds with the highest sustained load
(VO2peak) [ml
-1⋅kg-1⋅min-1]. Anaerobic power will be
determined using the 20 seconds Wingate Anaerobic
cycling Test (20s-WAnT), a sprint test against a con-
stant breaking torque [54]. Anaerobic fitness will be
defined by the mean anaerobic power over 20 seconds
(P20mean) [W⋅kg
-1] and by the highest power output
within the 20 seconds, the peak anaerobic power
(P20peak) [W⋅kg
-1]. Measurement procedures, equipment
and protocols for both tests will be as described by
Balemans et al. [53].
Other outcomes
Other study outcome measures will include 1) the
patient’s personal treatment goals, measured with Goal
Attainment Scaling (GAS), 2) treatment adherence,
assessed with a motivation diary and with the @monitor
[55], 3) satisfaction with the FRO, as perceived by the pa-
tient and parents and 4) FRO stiffness, measured with
BRUCE, which is a recently developed device for measur-
ing mechanical AFO properties [56].
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Subject population
Demographic variables and disease characteristics will
be summarised using descriptive statistics. Furthermore,
the means, medians, standard deviations and 95% confi-
dence interval (CI) of primary and secondary outcome
measures will be presented for all visits. In addition, cor-
relations between parameters will be examined using
correlation coefficients and graphical techniques.
Evaluation of FRO efficacy
Evaluation of the efficacy of a subject’s optimal FRO will
be based on analyses of pre/post-intervention differences
in primary and secondary outcome measures. The pre-
intervention (control) condition will be for shoes only.
Mean data for these measurements (assessed at T0) will
be compared to follow-up measurements (T2Kopt), using
paired sample t-tests.
To identify working mechanisms, multivariate linear
regression analyses will be applied to investigate which
of the changes in gait biomechanics are associated with
changes in walking energy cost (model 1) and daily
activity (model 2). First, a univariate regression analysis
(ANOVA) will be performed to determine which factors
are significantly associated with changes in the biomech-
anics of gait (p≤0.1), followed by the analysis of signifi-
cant factors (p≤.05) in a multivariate regression analysis
model.
Identifying prognostic factors
Multivariate regression analysis will also be applied to
investigate to what extent child characteristics and FRO
stiffness represent determinants for success of FRO
treatment, defined as decreased walking energy cost
(model 1), improvement in daily activity (model 2) and
positive GAS scores (model 3). Initially, a univariate re-
gression analysis (ANOVA) will be performed to deter-
mine which factors are significantly associated with FRO
treatment outcomes (p≤0.1). Significant factors (p≤.05)
will then be included in a multivariate regression model.
Model analysis will include factors such as level of phys-
ical fitness, baseline disease characteristics, gait pattern,
level of functional mobility, environmental factors and
FRO characteristics.Discussion
This study will evaluate the effects of varying degrees of
FRO ankle stiffness on different aspects of gait. Based on
earlier studies, an optimal match is expected between spe-
cific patient characteristics and FRO stiffness. Assuming
that there is an optimal FRO stiffness for each subject, this
study might lead directly to an optimised FRO treatment
for these patients. In addition, the study will evaluate FROefficacy, using outcome measures that are relevant in the
patient’s daily life (i.e. walking energy cost and daily activ-
ity), thereby emphasising clinical relevance.
Because the stiffness of an FRO should be based on the
specific gait deviations of the child, the inclusion criteria
of this study will be specifically defined. This will result in
a relatively homogeneous study population, enabling a fair
comparison of subjects. On the other hand, these strict
criteria may make it difficult to generalise results to the
wider treatment and prescription of FROs, also because
the design of the investigational FRO design differs from
conventional FROs. Nonetheless, it is expected that the
results of the study will allow an optimal FRO treatment
to be defined in this specific patient group.
This study will be the first to investigate broadly the effi-
cacy of an individually optimised FRO, including evalu-
ation of effects on multiple ICF levels. This will result in a
unique data set with which to assess mutual relations
between outcome measures. We anticipate that this ana-
lysis will aid in identifying both the underlying working
mechanisms of FRO and the factors important to treat-
ment success. In conclusion, the data generated by this
study may provide not only novel insights, but may also
contribute to improved FRO treatment in SCP in the
(near) term.
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